Contact Lenses-Medical Devices Pipeline Assessment, 2017

Table of Contents

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 7

1.2 List of Figures 11

2 Introduction 12

2.1 Contact Lenses Overview 12

3 Products under Development 13

3.1 Contact Lenses-Pipeline Products by Stage of Development 13

3.2 Contact Lenses-Pipeline Products by Segment 14

3.3 Contact Lenses-Pipeline Products by Territory 15

3.4 Contact Lenses-Pipeline Products by Regulatory Path 16

3.5 Contact Lenses-Pipeline Products by Estimated Approval Date 17

3.6 Contact Lenses-Ongoing Clinical Trials 18

4 Contact Lenses-Pipeline Products under Development by Companies 19

4.1 Contact Lenses Companies-Pipeline Products by Stage of Development 19

4.2 Contact Lenses-Pipeline Products by Stage of Development 21

5 Contact Lenses Companies and Product Overview 23

5.1 Aeon Astron Corporation Company Overview 23

5.1.1 Aeon Astron Corporation Pipeline Products Ongoing Clinical Trials Overview 23

5.2 Alcon Laboratories Inc Company Overview 25

5.2.1 Alcon Laboratories Inc Pipeline Products Ongoing Clinical Trials Overview 25

5.3 Apeliotus Ophthalmics (Inactive) Company Overview 33

5.3.1 Apeliotus Ophthalmics (Inactive) Pipeline Products Ongoing Clinical Trials Overview 33

5.4 Auburn University Company Overview 35

5.4.1 Auburn University Pipeline Products Ongoing Clinical Trials Overview 35

5.5 Axcelon Biopolymers Corp. Company Overview 36

5.5.1 Axcelon Biopolymers Corp. Pipeline Products Ongoing Clinical Trials Overview 36

5.6 Bar-Ilan University Company Overview 37

5.6.1 Bar-Ilan University Pipeline Products Ongoing Clinical Trials Overview 37

5.7 Bausch Lomb Inc Company Overview 38

5.7.1 Bausch Lomb Inc Pipeline Products Ongoing Clinical Trials Overview 38

5.8 Children's Hospital Boston Company Overview 42

5.8.1 Children's Hospital Boston Pipeline Products Ongoing Clinical Trials Overview 42

5.9 CooperVision Inc Company Overview 43

5.9.1 CooperVision Inc Pipeline Products Ongoing Clinical Trials Overview 43

5.10 EP Global Communications, Inc. Company Overview 48

5.10.1 EP Global Communications, Inc. Pipeline Products Ongoing Clinical Trials Overview 48

5.11 Euclid Systems Corp Company Overview 49

5.11.1 Euclid Systems Corp Pipeline Products Ongoing Clinical Trials Overview 49

5.12 e-Vision Medical Devices, Inc. Company Overview 50

5.12.1 e-Vision Medical Devices, Inc. Pipeline Products Ongoing Clinical Trials Overview 50

5.13 Eyenovations Company Overview 51

5.13.1 Eyenovations Pipeline Products Ongoing Clinical Trials Overview 51

5.14 EyeYon Medical Company Overview 52

5.14.1 EyeYon Medical Pipeline Products Ongoing Clinical Trials Overview 52

5.15 Imperial College London Company Overview 53

5.15.1 Imperial College London Pipeline Products Ongoing Clinical Trials Overview 53

5.16 Johnson Johnson Vision Care Inc Company Overview 54

5.16.1 Johnson Johnson Vision Care Inc Pipeline Products Ongoing Clinical Trials Overview 54

5.17 Massachusetts Eye and Ear Infirmary Company Overview 56

5.17.1 Massachusetts Eye and Ear Infirmary Pipeline Products Ongoing Clinical Trials Overview 56

5.18 Novartis AG Company Overview 57

5.18.1 Novartis AG Pipeline Products Ongoing Clinical Trials Overview 57

5.19 Ocular Dynamics, LLC Company Overview 58

5.19.1 Ocular Dynamics, LLC Pipeline Products Ongoing Clinical Trials Overview 58

5.20 Ocutec Ltd Company Overview 59

5.20.1 Ocutec Ltd Pipeline Products Ongoing Clinical Trials Overview 59

5.21 Presbia Plc Company Overview 60

5.21.1 Presbia Plc Pipeline Products Ongoing Clinical Trials Overview 60

5.22 RetMap Inc Company Overview 63

5.22.1 RetMap Inc Pipeline Products Ongoing Clinical Trials Overview 63

5.23 Stanford University Company Overview 64

5.23.1 Stanford University Pipeline Products Ongoing Clinical Trials Overview 64

5.24 SynergEyes Inc Company Overview 65

5.24.1 SynergEyes Inc Pipeline Products Ongoing Clinical Trials Overview 65

5.25 The Hong Kong University of Science and Technology Company Overview 67

5.25.1 The Hong Kong University of Science and Technology Pipeline Products Ongoing Clinical Trials Overview 67

5.26 The University of New South Wales Company Overview 68

5.26.1 The University of New South Wales Pipeline Products Ongoing Clinical Trials Overview 68

5.27 UltraVision CLPL Company Overview 69

5.27.1 UltraVision CLPL Pipeline Products Ongoing Clinical Trials Overview 69

5.28 University of California San Diego Company Overview 70

5.28.1 University of California San Diego Pipeline Products Ongoing Clinical Trials Overview 70

5.29 University of Florida Company Overview 72

5.29.1 University of Florida Pipeline Products Ongoing Clinical Trials Overview 72

5.30 University of Valencia Company Overview 73

5.30.1 University of Valencia Pipeline Products Ongoing Clinical Trials Overview 73

5.31 University of Washington Company Overview 75

5.31.1 University of Washington Pipeline Products Ongoing Clinical Trials Overview 75

5.32 Valeant Pharmaceuticals International Inc Company Overview 77

5.32.1 Valeant Pharmaceuticals International Inc Pipeline Products Ongoing Clinical Trials Overview 77

5.33 Visioneering Technologies Inc Company Overview 90

5.33.1 Visioneering Technologies Inc Pipeline Products Ongoing Clinical Trials Overview 90

5.34 VISTAKON Pharmaceuticals LLC Company Overview 94

5.34.1 VISTAKON Pharmaceuticals LLC Pipeline Products Ongoing Clinical Trials Overview 94

5.35 Yolia Health Company Overview 95

5.35.1 Yolia Health Pipeline Products Ongoing Clinical Trials Overview 95

6 Contact Lenses-Recent Developments 96

6.1 Jul 13, 2017: Visioneering Technologies Appoints Michelle Kirst as Territory Manager for New Jersey 96

6.2 Jul 11, 2017: Visioneering Technologies Appoints Ron Makelke as Territory Manager for San Francisco 96

6.3 Jul 06, 2017: Bausch + Lomb Japan Launches Bausch + Lomb AQUALOX Contact Lenses 97

6.4 Jul 06, 2017: Visioneering Technologies Appoints Carol Baez as Executive Territory Manager for Orange County/San Diego 97

6.5 Jun 29, 2017: Visioneering Technologies Announces Connie Stewart as Territory Manager, Los Angeles 98

6.6 Jun 27, 2017: Visioneering Technologies Names Mark Rapoport as New CFO 98

6.7 Jun 22, 2017: Bausch + Lomb Named Most Trusted Contact Lens Solution Brand In Canada For Second Consecutive Year By Brandspark International 99

6.8 Jun 20, 2017: Visioneering Technologies Announces Dave Halverson as Territory Manager in Southern California 99

6.9 Jun 19, 2017: Valeant Appoints Arthur J. Shannon As Senior Vice President, Head Of Investor Relations And Communications 100

6.10 Jun 19, 2017: John Paulson Joins Valeant Board Of Directors 100

6.11 Jun 13, 2017: KAMRA Corneal Inlay Helps College Administrator End Her Blurry Near Vision and Dependence on Reading Glasses 100

6.12 Jun 10, 2017: Three-Year Study Indicates Pioneering Contact Lens Therapy Effective in Slowing Myopia Progression in Children by 59% 101

6.13 Jun 10, 2017: Three-year study says new contact lens therapy slows myopia progression in children by 59 percent 102

6.14 Jun 01, 2017: The Cooper Companies Announces Second Quarter 2017 Results 103

6.15 Jun 01, 2017: The Cooper Companies Announces Second Quarter 2017 Results 104

6.16 May 30, 2017: The German Court has Granted a Preliminary Injunction in Favour of VSY Biotechnology BV and Against Carl Zeiss Meditec 105

6.17 May 23, 2017: Presbia Provides Update on US Staged Pivotal Clinical Trial For Flexivue Microlens 106

6.18 May 22, 2017: Bausch + Lomb Introduces renu Advanced Formula Multi-Purpose Solution 106

6.19 May 11, 2017: Hoya Reports Fourth Quarter and Full-Year Financial Results 107

6.20 May 10, 2017: Carl Zeiss Meditec accelerates growth in the first six months of 2016/17 108

6.21 May 09, 2017: Valeant Announces First Quarter 2017 Results And Raises Full Year Adjusted EBITDA Guidance Range 109

6.22 May 08, 2017: ZEISS Appoints New Fellow 109

6.23 May 08, 2017: Dr. Stephen S. Lane joins Alcon as Chief Medical Officer and Global Head Franchise Clinical Strategy 110

6.24 May 05, 2017: Valeant Announces Key Appointments In Dermatology And Corporate Communications Leadership 111

6.25 May 03, 2017: Presbia to Participate in the 2017 ASCRS Symposium Congress in Los Angeles, California 112

6.26 May 02, 2017: KAMRA Corneal Inlay Utilizes Camera Technology to Sharpen and Clear Blurry Near Vision for Patients 112

6.27 May 01, 2017: Visioneering Technologies Expands US Sales Force 113

6.28 Apr 25, 2017: Novartis delivered sales growth across all divisions as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued 113

6.29 Apr 25, 2017: Essilor International: Revenue increases by 10% Q1 in line with planned 2017 growth trajectory 117

6.30 Apr 04, 2017: Carl Zeiss Meditec Group achieves first half 2016/17 revenue of approximately EUR 588 million 120

6.31 Mar 30, 2017: Bausch + Lomb ULTRA For Astigmatism Contact Lenses Introduced 120

6.32 Mar 27, 2017: Visioneering Technologies Successfully Lists on ASX 121

6.33 Mar 15, 2017: Bausch + Lomb Introduces Biotrue ONEday For Astigmatism Contact Lenses 122

6.34 Mar 08, 2017: The KAMRA Corneal Inlay Brings Life Back into Focus for Patients with Presbyopia, Blurring Near Vision 122

6.35 Mar 03, 2017: Visioneering Technologies Announces Launch of NaturalVue Sphere 1 Day Contact Lenses 123

6.36 Mar 02, 2017: Johnson Johnson Vision Expands Portfolio to Reach More Patients with ACUVUE OASYS 1-DAY Brand Contact Lenses for ASTIGMATISM 124

6.37 Mar 02, 2017: The Cooper Companies Announces First Quarter Results 124

6.38 Feb 28, 2017: Valeant Reports Fourth Quarter And Full Year 2016 Financial Results And Provides 2017 Guidance 125

6.39 Feb 28, 2017: Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting 129

6.40 Feb 17, 2017: Essilor International Reports 2016 Financial Results 130

6.41 Feb 10, 2017: Carl Zeiss Meditec Off to A Solid Start Into Business Year 2016/17 137

6.42 Jan 31, 2017: Hoya Announces Third Quarter Financial Results 138

6.43 Jan 26, 2017: Novartis highlights progress towards access and environmental goals in 2016 Corporate Responsibility Performance Report 138

6.44 Jan 26, 2017: Achievement of sales milestone for COPD products 139

6.45 Jan 25, 2017: Novartis delivered solid 2016 performance, with Growth Products absorbing Gleevec US LOE; innovation momentum continued; announces share buyback 140

6.46 Jan 24, 2017: Visioneering Technologies Announces Pam Wyman as Director, Sales Operations Inside Sales 147

6.47 Jan 18, 2017: Bausch + Lomb Introduces Zen RC Scleral Contact Lenses 147

6.48 Jan 17, 2017: Visioneering Technologies Announces Jeff Babbe as New Executive Territory Manager for Chicago, IL 148

6.49 Jan 11, 2017: Paragon CRT Contact Lenses Approved by China Food Drug Administration 148

6.50 Jan 10, 2017: Bausch + Lomb Launches Expanded Parameters For Bausch + Lomb ULTRA For Presbyopia Contact Lenses 149

6.51 Jan 10, 2017: Bausch + Lomb ULTRA for Presbyopia Contact Lenses Parameters Expanded 150

6.52 Jan 10, 2017: Stephen Petranek Appointed to NexOptic Board 150

6.53 Jan 04, 2017: Valeant Pharmaceuticals Announces Addition Of Richard U. DeSchutter To Its Board Of Directors 151

6.54 Jan 04, 2017: First Contact Lenses Specifically Designed for Digital Lifestyles Makes their CES Debut 152

6.55 Dec 21, 2016: Visioneering Technologies Announces Brian Atkinson as Territory Manager for the Dallas/Ft. Worth Market 153

6.56 Dec 13, 2016: Visioneering Technologies Announces Ken Gold as New Executive Territory Manager for the Baltimore-Washington, DC Area 153

6.57 Dec 12, 2016: Bausch + Lomb Specialty Vision Products Launches New 28 Lens Zenlens Dx Set 154

6.58 Dec 12, 2016: Valeant Appoints William D. Humphries As EVP, Dermatology 154

6.59 Dec 09, 2016: Carl Zeiss Meditec continues its growth trend 155

6.60 Dec 08, 2016: The Cooper Companies Announces Fourth Quarter and Full Year 2016 Results 156

6.61 Dec 07, 2016: Essilor Realigns its Organization with its Growing Businesses 157

6.62 Dec 07, 2016: VTI names executive director of manufacturing and engineering 158

6.63 Dec 07, 2016: Visioneering Technologies Announces Ms. Rosa Lee as New Executive Director of Manufacturing Engineering 158

6.64 Nov 29, 2016: Novartis Access shares one-year learnings and announces memorandum of understanding with Rwanda 159

6.65 Nov 17, 2016: Former Valeant Executive And Former Philidor Ceo Charged In Manhattan Federal Court For Illegal Fraud And Kickback Scheme 160

6.66 Nov 10, 2016: Alcon introduces new AIR OPTIX plus HydraGlyde monthly replacement contact lenses at the American Academy of Optometry annual meeting 161

6.67 Nov 09, 2016: New Study Shows Groundbreaking Contact Lens Therapy Effective in Slowing Myopia Progression in Children by 59% Over Two Years 162

6.68 Nov 09, 2016: Daniel B. Polley, Ph.D., appointed Director of Lauer Tinnitus Research Center at Mass. Eye and Ear 164

6.69 Nov 08, 2016: Valeant Reports Third Quarter 2016 Financial Results 165

6.70 Oct 28, 2016: Hoya Reports Second Quarter Results 168

6.71 Oct 27, 2016: VTI Introduces the NaturalVue Multifocal QuickStart Calculator 169

6.72 Oct 26, 2016: Edmund Optics and Varioptic Announce the Availability of the Variable Focus Arctic Liquid Lens in the EO Catalog 169

6.73 Oct 25, 2016: Novartis delivered solid third quarter with Growth Products offsetting Gleevec patent expiration; several positive readouts for potential blockbusters 170

6.74 Oct 21, 2016: Essilor: Nine-Month Consolidated Revenue up 7.8% at Constant Exchange Rates 177

6.75 Oct 13, 2016: Carl Zeiss Meditec appoints Steven C. Schallhorn, MD as Chief Medical Officer 179

6.76 Oct 12, 2016: Bausch + Lomb Booth to Feature Wet Lab During the Annual Meeting of the American Academy of Ophthalmology in Chicago 180

6.77 Oct 06, 2016: Valeant Appoints Louis W. Yu, Ph.D. As Chief Quality Officer 182

6.78 Sep 01, 2016: The Cooper Companies CFO Gregory W. Matz to Retire; Albert G. White Named Successor in Planned Transition 183

6.79 Sep 01, 2016: The Cooper Companies Announces Third Quarter 2016 Results 184

6.80 Aug 29, 2016: Drug-dispensing contact lens effectively lowers eye pressure in pre-clinical glaucoma model 184

6.81 Aug 29, 2016: Drug Dispensing Contact lens Effectively Lowers Eye Pressure in Pre clinical Glaucoma Model 186

6.82 Aug 22, 2016: Valeant Pharmaceuticals Appoints Paul S. Herendeen As Executive Vice President, Finance And Chief Financial Officer 187

6.83 Aug 15, 2016: CooperVision Unveils Avaira Vitality Sphere and Toric Two-Week Contact Lenses 188

6.84 Aug 12, 2016: Carl Zeiss Meditec Grows in Ophthalmology and Microsurgery 189

6.85 Aug 11, 2016: Outcomes of Presbia Microlens Surgeries in Korean Study Demonstrate Excellent Results 190

6.86 Aug 10, 2016: Valeant Pharmaceuticals Comments On SDNY Investigation 190

6.87 Aug 09, 2016: Valeant Pharmaceuticals Reports Second Quarter 2016 Financial Results 190

6.88 Aug 08, 2016: Valeant Pharmaceuticals Announces Changes To Executive Management Team 192

6.89 Aug 01, 2016: Essilor International: Improving Lives by Improving Sight 194

6.90 Jul 29, 2016: Essilor-First-Half 2016 Results: Revenue Up 8.1% Excluding the Currency Effect 195

6.91 Jul 29, 2016: Hoya Reports First Quarter Financial Results 199

6.92 Jul 28, 2016: Valeant Pharmaceuticals Announces The Addition Of Sarah B. Kavanagh To Its Board Of Directors 199

6.93 Jul 27, 2016: Carl Zeiss Meditec Recruits James V. Mazzo to Lead Its Newly Consolidated Ophthalmology Organization 200

7 Appendix 201

7.1 Methodology 201

7.2 About GlobalData 204

7.3 Contact Us 204

7.4 Disclaimer 204

List of Figure

1.2 List of Figures

Figure 1: Contact Lenses-Pipeline Products by Stage of Development 13

Figure 2: Contact Lenses-Pipeline Products by Segment 14

Figure 3: Contact Lenses-Pipeline Products by Territory 15

Figure 4: Contact Lenses-Pipeline Products by Regulatory Path 16

Figure 5: Contact Lenses-Pipeline Products by Estimated Approval Date 17

Figure 6: Contact Lenses-Ongoing Clinical Trials 18

List of Table

1.1 List of Tables

Table 1: Contact Lenses-Pipeline Products by Stage of Development 13

Table 2: Contact Lenses-Pipeline Products by Segment 14

Table 3: Contact Lenses-Pipeline Products by Territory 15

Table 4: Contact Lenses-Pipeline Products by Regulatory Path 16

Table 5: Contact Lenses-Pipeline Products by Estimated Approval Date 17

Table 6: Contact Lenses-Ongoing Clinical Trials 18

Table 7: Contact Lenses Companies-Pipeline Products by Stage of Development 19

Table 8: Contact Lenses-Pipeline Products by Stage of Development 21

Table 9: Aeon Astron Corporation Pipeline Products Ongoing Clinical Trials Overview 23

Table 10: Biolens-Product Status 23

Table 11: Biolens-Product Description 23

Table 12: Contact Lens-Product Status 24

Table 13: Contact Lens-Product Description 24

Table 14: Alcon Laboratories Inc Pipeline Products Ongoing Clinical Trials Overview 25

Table 15: AIR OPTIX Plus HydraGlyde Monthly Replacement Clear And Color Lens-Product Status 25

Table 16: AIR OPTIX Plus HydraGlyde Monthly Replacement Clear And Color Lens-Product Description 26

Table 17: AIR OPTIX Plus HydraGlyde Monthly Replacement Contact Lenses-Overnight And Flexible Wear-Product Status 26

Table 18: AIR OPTIX Plus HydraGlyde Monthly Replacement Contact Lenses-Overnight And Flexible Wear-Product Description 26

Table 19: Dailies Total 1 Colors SiHy Lens-Product Status 27

Table 20: Dailies Total 1 Colors SiHy Lens-Product Description 27

Table 21: Dailies Total 1 Toric SiHy Lens-Product Status 27

Table 22: Dailies Total 1 Toric SiHy Lens-Product Description 27

Table 23: Smart Contact Lens-Diabetes-Product Status 28

Table 24: Smart Contact Lens-Diabetes-Product Description 28

Table 25: Weekly WG SiHy Lens-Product Status 28

Table 26: Weekly WG SiHy Lens-Product Description 29

Table 27: Alcon Laboratories Inc-Ongoing Clinical Trials Overview 30

Table 28: AIR OPTIX Plus HydraGlyde Monthly Replacement Contact Lenses-Overnight And Flexible Wear-Clinical Assessment of a Regimen of AIR OPTIX plus HYDRAGLYDE Silicone Hydrogel Lenses and HYDRAGLYDE Containing Lens Care Solutions 31

Table 29: AIR OPTIX Plus HydraGlyde Monthly Replacement Contact Lenses-Overnight And Flexible Wear-One-month Clinical Comparison of Silicone Hydrogel Monthly Lenses in High Lipid Depositors 31

Table 30: AIR OPTIX Plus HydraGlyde Monthly Replacement Clear And Color Lens-One-month Clinical Comparison of Silicone Hydrogel Monthly Lenses in High Lipid Depositors 32

Table 31: Apeliotus Ophthalmics (Inactive) Pipeline Products Ongoing Clinical Trials Overview 33

Table 32: Comfort Lens-Product Status 33

Table 33: Comfort Lens-Product Description 33

Table 34: Contact Lens-Glaucoma-Product Status 34

Table 35: Contact Lens-Glaucoma-Product Description 34

Table 36: Auburn University Pipeline Products Ongoing Clinical Trials Overview 35

Table 37: Smart Contact Lenses-Product Status 35

Table 38: Smart Contact Lenses-Product Description 35

Table 39: Axcelon Biopolymers Corp. Pipeline Products Ongoing Clinical Trials Overview 36

Table 40: MC-PHEMA Based Contact Lens-Product Status 36

Table 41: MC-PHEMA Based Contact Lens-Product Description 36

Table 42: Bar-Ilan University Pipeline Products Ongoing Clinical Trials Overview 37

Table 43: Bionic Contact Lens-Product Status 37

Table 44: Bionic Contact Lens-Product Description 37

Table 45: Bausch Lomb Inc Pipeline Products Ongoing Clinical Trials Overview 38

Table 46: Bausch + Lomb ULTRA Astigmatism Contact Lens-Product Status 38

Table 47: Bausch + Lomb ULTRA Astigmatism Contact Lens-Product Description 39

Table 48: Bausch + Lomb ULTRA Presbyopia Contact Lens-Product Status 39

Table 49: Bausch + Lomb ULTRA Presbyopia Contact Lens-Product Description 40

Table 50: Ultra Plus Powers Lens-Product Status 40

Table 51: Ultra Plus Powers Lens-Product Description 41

Table 52: Ultra Toric Lens-Product Status 41

Table 53: Ultra Toric Lens-Product Description 41

Table 54: Children's Hospital Boston Pipeline Products Ongoing Clinical Trials Overview 42

Table 55: Contact Lens Drug Delivery Device-Product Status 42

Table 56: Contact Lens Drug Delivery Device-Product Description 42

Table 57: CooperVision Inc Pipeline Products Ongoing Clinical Trials Overview 43

Table 58: Biofinity Energys-Product Status 43

Table 59: Biofinity Energys-Product Description 43

Table 60: MiSight Dual-Focus Myopia Control 1-Day Soft Contact Lens-Product Status 44

Table 61: MiSight Dual-Focus Myopia Control 1-Day Soft Contact Lens-Product Description 44

Table 62: SiH Multifocal-Product Status 44

Table 63: SiH Multifocal-Product Description 45

Table 64: CooperVision Inc-Ongoing Clinical Trials Overview 46

Table 65: MiSight Dual-Focus Myopia Control 1-Day Soft Contact Lens-A Multi-center Dispensing Clinical Evaluation of MiSight Lenses 47

Table 66: MiSight Dual-Focus Myopia Control 1-Day Soft Contact Lens-Efficacy and Safety of MiSight Contact Lenses in Reducing the Progression of Childhood Myopia, Not Pathological, Aged 8-12 Years Randomized Clinical Trial 47

Table 67: EP Global Communications, Inc. Pipeline Products Ongoing Clinical Trials Overview 48

Table 68: EP Global Contact Lens-Product Status 48

Table 69: EP Global Contact Lens-Product Description 48

Table 70: Euclid Systems Corp Pipeline Products Ongoing Clinical Trials Overview 49

Table 71: Drug-Eluting Contact Lenses-Product Status 49

Table 72: Drug-Eluting Contact Lenses-Product Description 49

Table 73: e-Vision Medical Devices, Inc. Pipeline Products Ongoing Clinical Trials Overview 50

Table 74: Electronic Contact Lens-Product Status 50

Table 75: Electronic Contact Lens-Product Description 50

Table 76: Eyenovations Pipeline Products Ongoing Clinical Trials Overview 51

Table 77: Drug Dispensing Contact Lens-Product Status 51

Table 78: Drug Dispensing Contact Lens-Product Description 51

Table 79: EyeYon Medical Pipeline Products Ongoing Clinical Trials Overview 52

Table 80: Hyper-CL-Drug Delivery-Product Status 52

Table 81: Hyper-CL-Drug Delivery-Product Description 52

Table 82: Imperial College London Pipeline Products Ongoing Clinical Trials Overview 53

Table 83: Contact Lens-Product Status 53

Table 84: Contact Lens-Product Description 53

Table 85: Johnson Johnson Vision Care Inc Pipeline Products Ongoing Clinical Trials Overview 54

Table 86: 1-DAY ACUVUE Multifocal Contact Lens-Product Status 54

Table 87: 1-DAY ACUVUE Multifocal Contact Lens-Product Description 54

Table 88: Anti-allergic Contact Lens-Product Status 55

Table 89: Anti-allergic Contact Lens-Product Description 55

Table 90: Massachusetts Eye and Ear Infirmary Pipeline Products Ongoing Clinical Trials Overview 56

Table 91: Therapeutic Contact Lens-Product Status 56

Table 92: Therapeutic Contact Lens-Product Description 56

Table 93: Novartis AG Pipeline Products Ongoing Clinical Trials Overview 57

Table 94: CLM041-Product Status 57

Table 95: CLM041-Product Description 57

Table 96: Ocular Dynamics, LLC Pipeline Products Ongoing Clinical Trials Overview 58

Table 97: Contact Lens-Dry Eye Disease-Product Status 58

Table 98: Contact Lens-Dry Eye Disease-Product Description 58

Table 99: Ocutec Ltd Pipeline Products Ongoing Clinical Trials Overview 59

Table 100: Third PEG Hydrogel Contact Lens-Product Status 59

Table 101: Third PEG Hydrogel Contact Lens-Product Description 59

Table 102: Presbia Plc Pipeline Products Ongoing Clinical Trials Overview 60

Table 103: Presbia Flexivue Microlens-Product Status 60

Table 104: Presbia Flexivue Microlens-Product Description 60

Table 105: Presbia Plc-Ongoing Clinical Trials Overview 61

Table 106: Presbia Flexivue Microlens-Prospective, Non-randomized, Unmasked, Multicenter Clinical Investigation of the Presbia Flexivue Microlens for the Improvement of Near Vision in Emmetropic Presbyopes 62

Table 107: RetMap Inc Pipeline Products Ongoing Clinical Trials Overview 63

Table 108: CLEAr Lens-Product Status 63

Table 109: CLEAr Lens-Product Description 63

Table 110: Stanford University Pipeline Products Ongoing Clinical Trials Overview 64

Table 111: Polymer Network Hydrogel Contact Lens-Product Status 64

Table 112: Polymer Network Hydrogel Contact Lens-Product Description 64

Table 113: SynergEyes Inc Pipeline Products Ongoing Clinical Trials Overview 65

Table 114: Duette Progressive With Tangible Hydra-PEG-Product Status 65

Table 115: Duette Progressive With Tangible Hydra-PEG-Product Description 65

Table 116: Duette With Tangible Hydra-PEG-Product Status 66

Table 117: Duette With Tangible Hydra-PEG-Product Description 66

Table 118: The Hong Kong University of Science and Technology Pipeline Products Ongoing Clinical Trials Overview 67

Table 119: Resonance Circuit Sensor Contact Lens-Product Status 67

Table 120: Resonance Circuit Sensor Contact Lens-Product Description 67

Table 121: The University of New South Wales Pipeline Products Ongoing Clinical Trials Overview 68

Table 122: Stem Cell Contact Lens-Product Status 68

Table 123: Stem Cell Contact Lens-Product Description 68

Table 124: UltraVision CLPL Pipeline Products Ongoing Clinical Trials Overview 69

Table 125: Contact Lenses-Product Status 69

Table 126: Contact Lenses-Product Description 69

Table 127: University of California San Diego Pipeline Products Ongoing Clinical Trials Overview 70

Table 128: Aerated Contact Lens-Product Status 70

Table 129: Aerated Contact Lens-Product Description 70

Table 130: Telescopic Contact Lens-Product Status 71

Table 131: Telescopic Contact Lens-Product Description 71

Table 132: University of Florida Pipeline Products Ongoing Clinical Trials Overview 72

Table 133: Vitamin E-Packed Lenses-Product Status 72

Table 134: Vitamin E-Packed Lenses-Product Description 72

Table 135: University of Valencia Pipeline Products Ongoing Clinical Trials Overview 73

Table 136: Multifocal Contact Lens-Myopia-Product Status 73

Table 137: Multifocal Contact Lens-Myopia-Product Description 73

Table 138: Multifocal Contact Lens-Presbyopia-Product Status 74

Table 139: Multifocal Contact Lens-Presbyopia-Product Description 74

Table 140: University of Washington Pipeline Products Ongoing Clinical Trials Overview 75

Table 141: Bionic Contact Lens-Product Status 75

Table 142: Bionic Contact Lens-Product Description 75

Table 143: Solar Powered Augmented Lenses-Product Status 76

Table 144: Solar Powered Augmented Lenses-Product Description 76

Table 145: Valeant Pharmaceuticals International Inc Pipeline Products Ongoing Clinical Trials Overview 77

Table 146: Biotrue ONEday Toric Lenses-ASTIGMATISM-Product Status 78

Table 147: Biotrue ONEday Toric Lenses-ASTIGMATISM-Product Description 78

Table 148: BLC-001: SVS-Product Status 78

Table 149: BLC-001: SVS-Product Description 79

Table 150: BLC-002: SVS-Product Status 79

Table 151: BLC-002: SVS-Product Description 79

Table 152: BLC-003: SVS/MF/fA-Product Status 80

Table 153: BLC-003: SVS/MF/fA-Product Description 80

Table 154: BLC-004: Toric-Product Status 80

Table 155: BLC-004: Toric-Product Description 81

Table 156: BLC-005: SVS/MF-Product Status 81

Table 157: BLC-005: SVS/MF-Product Description 81

Table 158: BLC-006: SVS-Product Status 82

Table 159: BLC-006: SVS-Product Description 82

Table 160: BLC-007: MF-Product Status 82

Table 161: BLC-007: MF-Product Description 83

Table 162: BLC-008: Astigmatism-Product Status 83

Table 163: BLC-008: Astigmatism-Product Description 83

Table 164: BLC-009: Astigmatism-Product Status 83

Table 165: BLC-009: Astigmatism-Product Description 84

Table 166: XUV-003: Aphakia-Product Status 84

Table 167: XUV-003: Aphakia-Product Description 84

Table 168: XUV-004: SVS-Product Status 84

Table 169: XUV-004: SVS-Product Description 85

Table 170: XUV-007: MF-Product Status 85

Table 171: XUV-007: MF-Product Description 85

Table 172: XUV-009: SVS-Product Status 86

Table 173: XUV-009: SVS-Product Description 86

Table 174: XUV-010: Astigmatism-Product Status 86

Table 175: XUV-010: Astigmatism-Product Description 87

Table 176: XUV-011: MF-Product Status 87

Table 177: XUV-011: MF-Product Description 87

Table 178: XUV-012: SVS-Product Status 87

Table 179: XUV-012: SVS-Product Description 88

Table 180: XUV-013: Astigmatism-Product Status 88

Table 181: XUV-013: Astigmatism-Product Description 88

Table 182: XUV-014: Presbyopia-Product Status 89

Table 183: XUV-014: Presbyopia-Product Description 89

Table 184: XUV-015: MF-Product Status 89

Table 185: XUV-015: MF-Product Description 89

Table 186: Visioneering Technologies Inc Pipeline Products Ongoing Clinical Trials Overview 90

Table 187: Contact Lens-Product Status 90

Table 188: Contact Lens-Product Description 90

Table 189: NaturalVue (etafilcon A) Sphere 1 Day Contact Lenses-Product Status 91

Table 190: NaturalVue (etafilcon A) Sphere 1 Day Contact Lenses-Product Description 91

Table 191: NaturalVue Toric 1 Day Contact Lenses-Product Status 91

Table 192: NaturalVue Toric 1 Day Contact Lenses-Product Description 92

Table 193: NaturalVue Toric Multifocal 1 Day Contact Lenses-Product Status 92

Table 194: NaturalVue Toric Multifocal 1 Day Contact Lenses-Product Description 92

Table 195: VTI MPC Lens-Product Status 93

Table 196: VTI MPC Lens-Product Description 93

Table 197: VISTAKON Pharmaceuticals LLC Pipeline Products Ongoing Clinical Trials Overview 94

Table 198: K-Lens-Product Status 94

Table 199: K-Lens-Product Description 94

Table 200: Yolia Health Pipeline Products Ongoing Clinical Trials Overview 95

Table 201: TVT Device-Product Status 95

Table 202: TVT Device-Product Description 95

Table 203: Glossary 203